We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
- Authors
Fleseriu, Maria; Newell-Price, John; Pivonello, Rosario; Shimatsu, Akira; Auchus, Richard J.; Scaroni, Carla; Belaya, Zhanna; Feelders, Richard A.; Vila, Greisa; Houde, Ghislaine; Walia, Rama; Izquierdo, Miguel; Roughton, Michael; Pedroncelli, Alberto M.; Biller, Beverly M. K.
- Abstract
Objective: To investigate the long-term efficacy and tolerability of osilod rostat, a potent oral 11ß-hydroxylase inhibitor, for treating Cushing's disease (CD). Design/methods: A total of 137 adults with CD and mean 24-h urinary free cortisol (mUFC) > 1.5 × upper limit of normal (ULN) received osilodrostat (starting dose 2 mg bid; maximum 30 mg bid) during the prospective, Phase III, 48-week LINC 3 (NCT02180217) core study. Patients benefiting from osilod rostat at week 48 could enter the optional extension (ending when all patients had received = 72 weeks of treatment or discontinued). Efficacy and safety were assessed for all enrolled patients from the core study baseline. Results: Median osilodrostat exposure from the core study baseline to study end was 130 weeks (range 1-245) and median average dose was 7.4 mg/day (range 0.8-46.6). The reduction in mean mUFC achieved during the core was maintained during the extension and remained = ULN. Of 106 patients, 86 (81%) patients who entered the extens ion had mUFC = ULN at week 72. Improvements in cardiovascular/metabolic-related parameters, physical manifestations of hypercortisolism (fat pads, central obesity, rubor, striae, and hirsutism in females), and quality of life in the core study were also maintained or improved further during the extension. No new safety signals were reported; 15/137 (10.9%) and 12/106 (11.3%) patients discontinued for adverse events during the core and extension, respectively. Mean testosterone in females decreased towards baseline levels during the extension. Conclusions: Data from this large, multicentre trial show that long-term treatment with osilodrostat sustains cortisol normalisation alongside clinical benefits in most patients with CD and is well tolerated.
- Subjects
CUSHING'S syndrome
- Publication
European Journal of Endocrinology, 2022, Vol 187, Issue 4, p531
- ISSN
0804-4643
- Publication type
Article
- DOI
10.1530/EJE-22-0317